| Assessment Status | Rapid Review Complete |
| HTA ID | 23052 |
| Drug | Doxylamine/pyridoxine |
| Brand | Cariban® |
| Indication | Doxylamine/pyridoxine (Cariban®) is indicated for the symptomatic treatment of nausea and vomiting during pregnancy in adults who do not respond to conservative management. |
| Assessment Process | |
| Rapid review commissioned | 11/08/2023 |
| Rapid review completed | 30/08/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Cariban®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
